Kaftrio (Tezacaftor, Elexacaftor, Ivacaftor)

The combination contains two CFTR correctors (tezacaftor and elexacaftor) that assist the misfolded CFTR protein to reach the cell surface, and a CFTR potentiator (ivacaftor) that increases the channel’s opening probability. Together they restore chloride transport across epithelial cells, addressing the underlying defect in cystic fibrosis.

The specific dosing regimen for Kaftrio is determined by the prescribing clinician based on the patient’s age, weight, genotype, and clinical status. Typically, the medication is taken as an oral tablet twice daily with a fat‑containing meal, but the exact schedule should follow the prescriber’s instructions.

Limited clinical data are available on the use of Kaftrio in pregnant or lactating individuals. It should only be used when the potential therapeutic benefit justifies any potential risk to the fetus or infant, and the decision should be made in consultation with a healthcare professional.

To request Kaftrio, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After the enquiry, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details, and any necessary import documentation.

Kaftrio contains the same three active components as other triple‑combination therapies such as Trikafta, offering comparable efficacy in patients with at least one F508del mutation. Differences may lie in formulation, regulatory approvals, and regional availability, but the core mechanism of correcting and potentiating CFTR function is shared.

Kaftrio tablets should be stored at ambient temperature, below 25 °C, in their original packaging. Keep the product away from moisture, direct sunlight, and excessive heat to maintain stability throughout its shelf life.

Kaftrio is taken orally as a tablet. The label advises swallowing the tablet whole with a meal that contains fat, which enhances absorption of the active ingredients. Doses are usually spaced about 12 hours apart, but patients should follow the exact schedule prescribed by their clinician.

Serious adverse events include significant liver injury (hepatitis), development of cataracts or other retinal changes, and severe allergic reactions such as anaphylaxis. Patients should be monitored regularly for liver function abnormalities and any visual disturbances, and they should seek immediate medical attention if signs of an allergic reaction appear.

Kaftrio is contraindicated in individuals with a known hypersensitivity to any of its components. Patients with severe hepatic impairment should avoid the medication, and those who are unable to take oral tablets with a fatty meal may not achieve adequate drug exposure. Clinicians should assess each patient’s medical history before initiating therapy.